The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants

Vaccine

Volumn 32, Issue 37, 2014, Pages 4726-4729

  Sande, Charles J ^a,d   Cane, Patricia A ^b   Nokes, D J ^a,c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immunity; Neutralising antibody; Respiratory syncytial virus

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

AGE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONVALESCENCE; HOSPITALIZATION; HUMAN; IMMUNITY; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; ANTIBODY PRODUCTION; BLOOD; IMMUNOLOGY; NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

AGE FACTORS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; VACCINATION;

EID: 84905219375     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.038     Document Type: Article

References (21)

1. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
2. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
3. Johnson J.E., Gonzales R.A., Olson S.J., Wright P.F., Graham B.S. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007, 20:108-119.
4. Munywoki P.K., Ohuma E.O., Ngama M., Bauni E., Scott J.A., Nokes D.J. Severe lower respiratory tract infection in early infancy and pneumonia hospitalizations among children, Kenya. Emerg Infect Dis 2013, 19:223-229.
5. Blanken M.O., Rovers M.M., Molenaar J.M., Winkler-Seinstra P.L., Meijer A., Kimpen J.L., et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013, 368:1791-1799.
6. Glezen W., Paredes A., Allison J., Taber L., Frank A. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98:708-715.
7. Piedra P.A., Jewell A.M., Cron S.G., Atmar R.L., Glezen W.P. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003, 21:3479-3482.
8. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
9. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
10. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8:497-502.
11. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182:1331-1342.
12. Wright P.F., Karron R.A., Belshe R.B., Shi J.R., Randolph V.B., Collins P.L., et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007, 25:7372-7378.
13. Nokes D.J., Ngama M.J., Bett A., Abwao J., Munywoki P., English M., et al. Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. Clin Infect Dis 2009, 49:1341-1349.
14. Scott J.A., Bauni E., Moisi J.C., Ojal J., Gatakaa H., Nyundo C., et al. Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol 2012, 41:650-657.
15. Sande C.J., Mutunga M.N., Medley G.F., Cane P.A., Nokes D.J. Group and genotype specific neutralising antibody responses against respiratory syncytial virus (RSV) in infants and young children with severe pneumonia. J Infect Dis 2012.
16. Brandenburg A., Groen J., Steensel-Moll H., Claas E., Rothbarth P., Neijens H., et al. Repiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997, 52:97-104.
17. Shinoff J.J., O'Brien K.L., Thumar B., Shaw J.B., Reid R., Hua W., et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008, 198:1007-1015.
18. Crowe J.E. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 2001, 33:1720-1727.
19. Ohuma E.O., Okiro E.A., Ochola R., Sande C.J., Cane P.A., Medley G.F., et al. The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol 2012, 176:794-802.
20. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE 2012, 7:e50852.
21. Glenn G.M., Smith G., Fries L., Raghunandan R., Lu H., Zhou B., et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31:524-532.